{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T15:12:11Z","timestamp":1761664331258,"version":"build-2065373602"},"reference-count":30,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Reumatolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.reuma.2017.11.007","type":"journal-article","created":{"date-parts":[[2017,12,19]],"date-time":"2017-12-19T23:22:41Z","timestamp":1513725761000},"page":"338-342","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Metotrexato en pacientes con artritis reumatoide en Espa\u00f1a: suban\u00e1lisis del proyecto AR Excellence"],"prefix":"10.1016","volume":"15","author":[{"given":"Jes\u00fas","family":"Tornero-Molina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Luis","family":"Andreu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda-Auxiliadora","family":"Mart\u00edn-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9ctor","family":"Corominas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Javier","family":"P\u00e9rez Venegas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Andr\u00e9s","family":"Rom\u00e1n-Ivorra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"S\u00e1nchez-Alonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.reuma.2017.11.007_bib0155","doi-asserted-by":"crossref","first-page":"168","DOI":"10.2174\/1573397112666160824151801","article-title":"Low-dose methotrexate (LD-MTX) in rheumatology practice-a most widely misunderstood drug","volume":"12","author":"Malaviya","year":"2016","journal-title":"Curr Rheumatol Rev"},{"key":"10.1016\/j.reuma.2017.11.007_bib0160","first-page":"279","article-title":"2014 update of the consensus statement of the Spanish Society of Rheumatology on the use of biological therapies in rheumatoid arthritis","volume":"11","author":"Sanmarti","year":"2015","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.reuma.2017.11.007_bib0165","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jbspin.2014.05.002","article-title":"Recommendations of the French Society for Rheumatology fot managing rheumatoid arthritis","volume":"81","author":"Gaujoux-Viala","year":"2014","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.reuma.2017.11.007_bib0170","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reuma.2017.11.007_bib0175","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.3899\/jrheum.121316","article-title":"Determining best practices in early rheumatoid arhritis by comparing differences in treatment at sites in the Canadian Early Arthitis Cohort","volume":"40","author":"Harris","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.reuma.2017.11.007_bib0180","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.reuma.2014.02.012","article-title":"Recommendations for the use of methotrexate in rheumatoid arthritis: Up and down scaling of the dose and administration routes","volume":"11","author":"Tornero Molina","year":"2015","journal-title":"Reumatol Clin"},{"issue":"71 Suppl","key":"10.1016\/j.reuma.2017.11.007_bib0185","first-page":"s33","article-title":"Evidence that the Strategy is more important tan the agent to treat rheumatoid arthritis data from clinical trials of combinations of non-biologic DMARDs, with protocol-driven intensification of therapy for tight control or treat-to-target","volume":"1","author":"Pincus","year":"2013","journal-title":"Bull Hosp Jt Dis"},{"key":"10.1016\/j.reuma.2017.11.007_bib0190","first-page":"1","article-title":"2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reuma.2017.11.007_bib0195","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1007\/s00296-015-3363-5","article-title":"Synthetic disease modifying antirheumatic drug prescribing variability in rheumatoid arthritis: A multilevel analysis of a cross sectional national study","volume":"35","author":"Ferraz-Amaro","year":"2015","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.reuma.2017.11.007_bib0200","article-title":"Recomendaciones sobre el uso de metotrexato parenteral en enfermedades reum\u00e1ticas","author":"Tornero Molina","year":"2017","journal-title":"Reumatol Clin."},{"key":"10.1016\/j.reuma.2017.11.007_bib0205","article-title":"Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis","volume":"8","author":"Hazlewood","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.reuma.2017.11.007_bib0210","article-title":"A composite indicator to assess the quality of care in the management of patients with rheumatoid arthritis in outpatient rheumatology clinics","volume":"5","author":"Mart\u00edn-Mart\u00ednez","year":"2017","journal-title":"Reumatol Clin."},{"key":"10.1016\/j.reuma.2017.11.007_bib0215","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reuma.2017.11.007_bib0220","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/1756-185X.12862","article-title":"Landmark papers on the discovery of methotrexate for the treatment of rheumatoid arthrtitis and other systemic inflammatory rheumatic diseases: A fascinating story","volume":"19","author":"Malaviya","year":"2016","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.reuma.2017.11.007_bib0225","article-title":"Methotrexate for treating rheumatoid arthritis","volume":"10","author":"L\u00f3pez-Olivo","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.reuma.2017.11.007_bib0230","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4081\/reumatismo.2013.207","article-title":"Systematic review of 2008-2012 literature and update of recommendations for the use of methotrexate in rheumatic diseases, with a focus on rheumatoid arthritis","volume":"65","author":"Todoerti","year":"2013","journal-title":"Reumatismo"},{"key":"10.1016\/j.reuma.2017.11.007_bib0235","first-page":"S1","article-title":"Methotrexate \u2014the anchor drug \u2014an introduction","volume":"28","author":"Pincus","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.reuma.2017.11.007_bib0240","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJM199605163342002","article-title":"Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications","volume":"334","author":"O\u2019Dell","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.reuma.2017.11.007_bib0245","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.clinthera.2014.01.014","article-title":"Methotrexate in rheumatoid arthrtitis: Optimizing therapy among different formulations. Current and emergent paradigms","volume":"36","author":"Cipriani","year":"2014","journal-title":"Clin Ther"},{"key":"10.1016\/j.reuma.2017.11.007_bib0250","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/art.23144","article-title":"Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: Results of a six-month, multicenter, randomized, double-blind, controlled, phase iv trial","volume":"58","author":"Braun","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reuma.2017.11.007_bib0255","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1136\/annrheumdis-2014-205228","article-title":"Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: Drug-exposure limitations of oral methotrexate at doses 15mg may be overcome with subcutaneous administration","volume":"73","author":"Schiff","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reuma.2017.11.007_bib0260","first-page":"645","article-title":"Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis","volume":"31","author":"Hoekstra","year":"2004","journal-title":"J Rheumatol."},{"key":"10.1016\/j.reuma.2017.11.007_bib0265","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/rheumatology\/36.3.345","article-title":"Comparison of intramuscular methotrexate and gold sodium thiomalate in the treatment of early erosive rheumatoid arthritis: 12 month data of a double-blind parallel study of 174 patients","volume":"36","author":"Rau","year":"1997","journal-title":"Br J Rheumatol."},{"key":"10.1016\/j.reuma.2017.11.007_bib0270","first-page":"3831","article-title":"Oral to subcutaneous methotrexate dose-conversion strategies in the treatment of rheumatoid arthritis","volume":"67","author":"Schiff","year":"2015","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reuma.2017.11.007_bib0275","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1136\/ard.2007.071092","article-title":"Intensive treatment with methotrexate in early rheuma- toid arthritis: Aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial)","volume":"66","author":"Verstappen","year":"2007","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2017.11.007_bib0280","doi-asserted-by":"crossref","unstructured":"Blanco F, Carbonell J, Tornero J, Mol\u00e0 O, Galv\u00e1n J. Condicionantes demogr\u00e1ficos y cl\u00ednicos para la elecci\u00f3n inicial de la v\u00eda de administraci\u00f3n de metotrexato y motivos para un posterior cambio de v\u00eda (Estudio MOTICAR). Acta Reumatol\u00f3gica. 2015;2:2386-6861. [acceso 12 Dic 2017]. Disponible en: http:\/\/imed.pub\/ojs\/index.php\/ar\/article\/view\/1039","DOI":"10.3823\/1316"},{"issue":"Suppl 10","key":"10.1016\/j.reuma.2017.11.007_bib0285","article-title":"Under use of methotrexate (MTX) in the treatment of rheumatoid arthritis (RA) in the United States (US): Results of a comprehensive pharmaceutical claims analysis [abstract]","volume":"67","author":"O\u2019Dell","year":"2015","journal-title":"Arthritis Rheum"},{"issue":"Suppl 10","key":"10.1016\/j.reuma.2017.11.007_bib0290","article-title":"Rheumatoid Arthritis (RA): Premature use of biologics accelerating in United States (US) [abstract]","volume":"68","author":"O\u2019Dell","year":"2016","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reuma.2017.11.007_bib0295","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.semarthrit.2012.12.001","article-title":"Factors associated with adherence to pharmaceutical treatment for rheumatoid arthritis patients: A systematic review","volume":"43","author":"Pasma","year":"2013","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.reuma.2017.11.007_bib0300","article-title":"Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis","volume":"Issue5","author":"Shea","year":"2013","journal-title":"Cochrane Database Syst Rev."}],"container-title":["Reumatolog\u00eda Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1699258X17302814?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1699258X17302814?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T14:58:43Z","timestamp":1761663523000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1699258X17302814"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S1699258X17302814"],"URL":"https:\/\/doi.org\/10.1016\/j.reuma.2017.11.007","relation":{},"ISSN":["1699-258X"],"issn-type":[{"type":"print","value":"1699-258X"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metotrexato en pacientes con artritis reumatoide en Espa\u00f1a: suban\u00e1lisis del proyecto AR Excellence","name":"articletitle","label":"Article Title"},{"value":"Reumatolog\u00eda Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.reuma.2017.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Reumatolog\u00eda y Colegio Mexicano de Reumatolog\u00eda. All rights reserved.","name":"copyright","label":"Copyright"}]}}